Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864734 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00864734 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 24 participants.
The verdict
NCT00864734, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Purepac Pharmaceutical Co. with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers under non-fasting conditions.
Interventions
- DRUG Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
- DRUG CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-11 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864734
The ClinicalTrials.gov registry entry for NCT00864734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg is the first listed.
NCT00864734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864734 about?
NCT00864734 is a clinical study titled "A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions". The purpose of this study is to compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Purepac Pharmaceutical Co. with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy ad...
What is the current status of trial NCT00864734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-11. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00864734?
The interventions under investigation include: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg (DRUG), CLUCOVANCE® 5 mg/500 mg Tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00864734?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.